Evidence-led profiles of lesser-known cannabinoids, their analytical challenges and implications for product development.
This hub connects focused technical articles with ECI's existing knowledge, quality and professional-development content.
The objective is to define and maintain controls that ensure identity, consistency, safety and fitness for the intended use.
The applicable framework depends on jurisdiction, intended use, product classification and lifecycle stage. EU GMP, pharmacopoeial and product-specific requirements may all be relevant.
No. Testing is only one element of assurance. Supplier controls, process understanding, qualification, in-process monitoring and data governance are also required.
Specifications should be scientifically justified using process capability, safety considerations, stability data, pharmacopoeial requirements and the intended clinical or technical use.
Trending can reveal gradual drift, supplier changes or method deterioration before individual results breach an acceptance limit.